ID: ALA52877

Max Phase: Preclinical

Molecular Formula: C30H38O8

Molecular Weight: 526.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCc1c(OCCC(C)(C)CCOc2cc3c(cc2C(C)=O)CCC(C(=O)O)O3)ccc(C(C)=O)c1O

Standard InChI:  InChI=1S/C30H38O8/c1-6-7-22-24(11-9-21(18(2)31)28(22)33)36-14-12-30(4,5)13-15-37-27-17-26-20(16-23(27)19(3)32)8-10-25(38-26)29(34)35/h9,11,16-17,25,33H,6-8,10,12-15H2,1-5H3,(H,34,35)

Standard InChI Key:  FXJVVVWLAOBUCU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 526.63

Molecular Weight (Monoisotopic): 526.2567

AlogP: 5.79

#Rotatable Bonds: 13

Polar Surface Area: 119.36

Molecular Species: ACID

HBA: 7

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.21

CX Basic pKa:

CX LogP: 5.95

CX LogD: 2.50

Aromatic Rings: 2

Heavy Atoms: 38

QED Weighted: 0.31

Np Likeness Score: 0.46

References

1. Cohen N, Weber G, Banner BL, Lopresti RJ, Schaer B, Focella A, Zenchoff GB, Chiu AM, Todaro L, O'Donnell M..  (1989)  3,4-Dihydro-2H-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists.,  32  (8): [PMID:2547071] [10.1021/jm00128a028]

Source

Source(1):

• Scientific Literature